Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Syndax Pharmaceuticals Inc (SNDX)  
$20.97 0.78 (3.59%) as of 4:30 Mon 5/13


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 94,014,000
Market Cap: 1.97(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $11.39 - $24.57
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of cancer therapies. Co.'s two primary product candidates are, SNDX-5613 and SNDX-6352 or axatilimab. Co. is developing SNDX-5613, targeting the binding interaction of menin with the mixed lineage leukemia 1 (MLL1) protein for the treatment of MLL-rearranged acute leukemias and nucleophosmin 1 mutant acute myeloid leukemia, as well as axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor. Co. has a collaboration and license agreement with Incyte Corporation for the development and commercialization of axatilimab.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 0 242,142 1,322,814
Total Sell Value $0 $0 $4,873,574 $30,131,894
Total People Sold 0 0 3 8
Total Sell Transactions 0 0 5 37
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 208
  Page 8 of 9  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Metzger Michael A President and COO   •       •      –    2020-11-04 4 AS $20.31 $2,031,410 D/D (100,000) 17,659 22%     
   Metzger Michael A President and COO   •       •      –    2020-11-04 4 OE $7.20 $720,000 D/D 100,000 117,659     -
   Meyers Michael L. SVP, Chief Medical Officer   •       –      –    2020-07-31 4 A $7.97 $21,240 D/D 2,665 13,395     -
   Meyers Michael L. SVP, Chief Medical Officer   •       –      –    2020-07-06 4 A $0.00 $0 D/D 3,500 10,730     -
   Metzger Michael A President and COO   •       •      –    2020-02-12 4 A $0.00 $0 D/D 15,000 17,659     -
   Morrison Briggs Chief Executive Officer   •       •      –    2020-02-04 4 B $8.00 $100,000 D/D 12,500 43,900 0.01 50%     
   Shea Richard P Chief Financial Officer   •       –      –    2020-01-31 4 A $7.97 $11,995 D/D 1,505 7,121     -
   Morrison Briggs Chief Executive Officer   •       •      –    2019-10-10 4 B $5.40 $59,400 D/D 11,000 31,400 0.01     -
   Shea Richard P Chief Financial Officer   •       –      –    2019-07-31 4 A $4.89 $6,851 D/D 1,401 5,616     -
   Morrison Briggs Chief Executive Officer   •       •      –    2019-05-13 4 B $7.29 $52,517 D/D 7,200 20,400 0.01     -
   Morrison Briggs Chief Executive Officer   •       •      –    2019-05-09 4 B $7.56 $99,726 D/D 13,200 13,200 0.01     -
   Meyers Michael L. SVP, Chief Medical Officer   •       –      –    2019-03-21 4/A B $4.87 $39 D/D 8 7,230 0.01     -
   Meyers Michael L. SVP, Chief Medical Officer   •       –      –    2019-03-21 4 B $4.87 $5,436 D/D 1,104 7,222 0.01     -
   Metzger Michael A President and COO   •       –      –    2019-01-31 4 A $4.76 $12,657 D/D 2,659 2,659     -
   Shea Richard P Chief Financial Officer   •       –      –    2019-01-31 4 A $4.76 $12,000 D/D 2,521 4,215     -
   Meyers Michael L. SVP, Chief Medical Officer   •       –      –    2019-01-31 4 A $4.76 $17,707 D/D 3,720 6,118     -
   Meyers Michael L. SVP, Chief Medical Officer   •       –      –    2018-10-30 4 B $4.79 $958 D/D 200 2,398 0.01     -
   Lampert Mark N 10% Owner   –       –       •   2018-06-18 4 D $0.00 $0 D/D (2,000,000) 85,038     -
   Ordentlich Peter Chief Scientific Officer   •       –      –    2018-04-03 4 AS $15.00 $112,500 D/D (7,500) 0     -
   Ordentlich Peter Chief Scientific Officer   •       –      –    2018-04-03 4 OE $3.08 $23,100 D/D 7,500 7,500     -
   Ordentlich Peter Chief Scientific Officer   •       –      –    2017-05-17 4 AS $15.00 $75,000 D/D (5,000) 0     -
   Ordentlich Peter Chief Scientific Officer   •       –      –    2017-05-17 4 OE $3.08 $2,255 D/D 732 5,000     -
   Royston Ivor   –       •      –    2017-03-20 4 D $13.75 $1,718,750 I/I (125,000) 625,545     -
   Mpm Bioventures Iv Strategic Fund, L.p. 10% Owner   –       –       •   2016-03-08 4 A $0.00 $0 I/I 2,168,691 2,168,691     -
   Halak Brian K 10% Owner   –       –       •   2016-03-08 4 A $0.00 $0 D/D 5,641 5,641     -
  208 Records found
  1  2  3  4  5  6  7  8  9   
  Page 8 of 9
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us